In this AMP 2022 session, Dr. McCready examines mutation profiles in AML and MDS from a large Southern Ontario cohort utilising two NGS panels, including OGT’s SureSeq Myeloid™ NGS panel.
Dr. McCready illustrates how the SureSeq Myeloid NGS portfolio provides her lab with robust detection of somatic mutations in high GC- content genes such as CEBPA and structural variants such as IDTs in the FLT3 gene, among others.
Dr. Elizabeth McCready, PhD, FCCMG
Dr. McCready’s research activities are largely translational in nature, with particular interest in application of molecular cytogenetic techniques to characterise clinically relevant genetic variants that contribute to developmental disorders and cancer.
View Dr. Elizabeth McCready's profile on LinkedIn
This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.
SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.